Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q4 EPS by 131c
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q4 EPS of ($1.92), $1.31 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $240.73 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
- Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c
- Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
